In older adult patients with LC harbouring an EGFR mutation, several observational studies support the safety and efficacy of EGFR tyrosine kinase inhibitors (TKIs) in first line, but there are concerns about a higher risk of toxicity. The gene discussed is EGFR; the disease is laryngotracheoesophageal cleft.